StockNews.AI
OTLK
StockNews.AI
62 days

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

1. OTLK will hold a Virtual Investor Lunch on June 25. 2. Key executives will discuss commercial strategy and upcoming milestones. 3. ONS-5010/LYTENAVA™ aims to enhance treatment options for retinal diseases. 4. The product has received marketing authorization in Europe for wet AMD. 5. A BLA for ONS-5010/LYTENAVA™ has been resubmitted to the FDA.

4m saved
Insight
Article

FAQ

Why Bullish?

Approval, if granted, could significantly enhance OTLK's market position, similar to past FDA approvals in biotechnology that led to increased stock value.

How important is it?

The announcement signifies key strategic developments and potential FDA approval, influencing investor sentiment and stock performance significantly.

Why Long Term?

The commercial success of LYTENAVA™ depends on FDA approval, impacting revenues and investor confidence over time.

Related Companies

AVEOAXSMPFE
Live webcast on Wednesday, June 25th at 12:00 PM ET June 18, 2025 09:05 ET  | Source: Outlook Therapeutics, Inc. ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP – Head of Europe, will discuss the Company’s commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed. Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD. In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD. Investor Inquiries: Jenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775OTLK@jtcir.com

Related News